Beijing Hotgen Biotech Co., Ltd. (SHA:688068)

China flag China · Delayed Price · Currency is CNY
132.50
-1.50 (-1.12%)
Mar 9, 2026, 3:00 PM CST
42.02%
Market Cap 11.77B
Revenue (ttm) 407.69M
Net Income (ttm) -210.52M
Shares Out 88.83M
EPS (ttm) -2.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,301,724
Average Volume 1,557,245
Open 133.14
Previous Close 134.00
Day's Range 130.02 - 134.24
52-Week Range 70.34 - 262.22
Beta 1.47
RSI 42.97
Earnings Date Apr 25, 2026

About Beijing Hotgen Biotech

Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers public safety solutions such as drug tasting, customs disease control, bioterrorism and food safety solutions. The company also provides clinical diagnostics and product solutions, including upconversion light, chemiluminescence, sugar capture, microfluidics, and genetic testing for testing of intestinal microorganisms, gastrointestina... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 850
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688068
Full Company Profile

Financial Performance

In 2025, Beijing Hotgen Biotech's revenue was 407.69 million, a decrease of -20.20% compared to the previous year's 510.90 million. Losses were -210.52 million, 10.2% more than in 2024.

Financial Statements

News

There is no news available yet.